Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients

Trial Profile

An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms POEM
  • Sponsors Pfizer; ViiV Healthcare
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 31 Oct 2018 to 26 Feb 2019.
    • 28 Jun 2017 Planned primary completion date changed from 31 Oct 2018 to 26 Feb 2019.
    • 17 May 2017 Planned End Date changed from 1 Oct 2018 to 31 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top